Stock DSGN DESIGN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Design Therapeutics, Inc.

Equities

DSGN

US25056L1035

Real-time Estimate Cboe BZX
Other stock markets
 12:38:50 2024-05-14 pm EDT 		5-day change 1st Jan Change
4.515 USD -0.77% Intraday chart for Design Therapeutics, Inc. -3.73% +70.38%
May. 08 Design Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 07 Piper Sandler Upgrades Design Therapeutics to Overweight From Neutral MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
GL
Design Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Piper Sandler Upgrades Design Therapeutics to Overweight From Neutral
MT
Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
GL
Sector Update: Health Care Stocks Ease Late Afternoon
MT
Sector Update: Health Care Stocks Down Wednesday Afternoon
MT
Design Therapeutics Stock Rises as RBC Says Q4 Results, Product Candidate Updates Show Progress
MT
Design Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
GL
Design Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
North American Morning Briefing : Stock Futures -2-
DJ
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update
GL
Design Therapeutics, Inc.(NasdaqGS:DSGN) dropped from NASDAQ Biotechnology Index
CI
RBC Cuts Price Target on Design Therapeutics to $4 From $7 Amid Limited Near-Term Clinical Updates, Keeps Sector Perform, Speculative Risk
MT
Wedbush Trims Design Therapeutics' PT to $5 From $6, Says Waiting for 2024 Strategic Update; Maintains Neutral Rating
MT
Design Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024
GL
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN
PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN
PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DSGN Stock
  4. News Design Therapeutics, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW